Additionally, potential combinations between P-AscH− and SOD mimetics present another noteworthy research direction that may hold value in overcoming resistance to conventional therapy and/or the limitations of P-AscH− and SOD mimetics, with Heer et al. recently reporting that the combination of P-AscH− and AVA significantly enhanced cancer cell killing in NSCLC and squamous cell carcinoma [188]. Here, SOD1 is linked to non-small cell lung carcinoma.